CULTURE BRANDS UNIVERSITIES UNITED NATIONS
HOME SUBSCRIBE ABOUT US CONTACT US


Global Goals

Press Freedom Day

UNESCO CREATIVE CITIES NETWORK




« Lucy Hale Joins ALMAY As Global Brand Ambassador | Main | Self-Sterilizing, Transparent N99+ Masks »

May 13, 2020

Cipla Enters Into a Licensing Agreement With Gilead to Expand Access to COVID-19 Treatment

Cipla

MUMBAI, India, May 13, 2020 — Cipla Limited today announced that it had signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine Remdesivir. This agreement is part of Cipla’s efforts to enhance global access to life-saving treatments for patients affected by the pandemic. Remdesivir has been issued an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat COVID-19 patients.

As part of the agreement, Gilead Sciences would permit Cipla to manufacture the API (Active Pharmaceutical Ingredient) and Finished Product and market it in 127 countries, including India and South Africa, under Cipla’s brand name. Cipla will receive the manufacturing know-how from Gilead Sciences, Inc. to manufacture the API and Finished Product at a commercial scale. Cipla’s extensive geographical and retail footprint will help make this therapy accessible to more patients and markets.

According to the World Health Organisation (WHO)’s tracker, the number of reported COVID-19 cases has crossed the four million mark globally.

The EUA will facilitate the broader use of Remdesivir to treat hospitalized patients with severe symptoms of COVID-19. The EUA is based on available data from two global clinical trials - the U.S. National Institute for Allergy and Infectious Diseases’ placebo-controlled Phase 3 study in patients with moderate to severe symptoms of COVID-19, and Gilead’s global Phase 3 study evaluating Remdesivir in patients with severe disease. Multiple additional clinical trials are ongoing to generate more data on the safety and efficacy of Remdesivir as a potential treatment for COVID-19. Remdesivir continues to be an investigational drug that has not been approved by the FDA.

Commenting on the partnership, Mr. Umang Vohra, MD and Global CEO, Cipla Limited, said, “As the world faces the COVID-19 crisis, we must collaborate and fight this virus together. We are pleased to partner with Gilead for this cause and take this treatment to patients across countries after the required regulatory approvals. At Cipla, it is our continuous endeavor to ensure that no patient is denied access to life-saving treatments. Our partnership with Gilead represents this unwavering commitment and is a significant step towards saving millions of lives impacted by the pandemic.”

Source: Cipla.

|GlobalGiants.Com|


del.icio.us StumbleUpon reddit Facebook Google Plus Tweet This Seed This on Newsvine

Edited & Posted by Surender Hastir | 1:31 PM | Link to this Post


Start from HOME Go to Top


TRANS WORLD EXPORTS


  DMCA.com Protection Status